Administration Provides More Data on First 10 Drugs Subject to Price Negotiation
January 4, 2024
Last month, the office of the Assistant Secretary for Planning and Evaluation (ASPE), a research arm of the Department of
📢 Action Needed: Tell Congress to Protect Federal Funding
Prescription Drugs
The Inflation Reduction Act (IRA) takes important steps to reduce drug prices and lower costs for people with Medicare and the program, such as capping beneficiary out-of-pocket spending; requiring Medicare to negotiate drug prices; and expanding eligibility for the full Part D low-income subsidy (LIS). We support an implementation process that centers the beneficiary experience and look forward to building upon these landmark policies.
Medicare Rights Joins Legal Fight in Defense of Drug Price Negotiation
November 16, 2023
Last week, the Medicare Rights Center joined with other advocacy organizations to urge a federal court to reject claims by
Medicare Prescription Payment Plan (MPPP) Draft Guidance
October 25, 2023
The Medicare Rights Center (Medicare Rights) appreciates this opportunity to comment on the Medicare Prescription Payment Plan (MPPP) draft guidance. Medicare Rights is a national, nonprofit organization that works to ensure access to affordable and equitable health care for older adults and people with disabilities through counseling and advocacy, educational programs, and public policy initiatives. Each year, Medicare Rights provides services and resources to over three million people with Medicare, family caregivers, and professionals.
Government Watchdog Urges Caution and Monitoring of Part D Rebate Programs
October 19, 2023
Last month, the Government Accountability Office (GAO) recommended that the Centers for Medicare & Medicaid Services monitor the effects of
Part D Drug Negotiations Move Forward
October 12, 2023
Last week, the Centers for Medicare & Medicaid Services (CMS) announced that all of the manufacturers of the first 10
Part D and Medicare Advantage Plans Stable for 2024
September 27, 2023
In advance of the upcoming Medicare Fall Open Enrollment period, beginning October 15, the Biden-Harris administration announced that Medicare Advantage
CMS Announces First 10 Drugs Subject to Price Negotiation
August 31, 2023
On Tuesday, the Centers for Medicare & Medicaid Services (CMS) announced the first 10 Medicare Part D drugs that will
Centers for Medicare & Medicaid Services Announces First 10 Medicare Part D Drugs Subject to Negotiation Under the Inflation Reduction Act (IRA)
August 29, 2023
—Statement by Fred Riccardi, President of the Medicare Rights Center– Washington DC—The Medicare Rights Center applauds a historic milestone achieved
Inflation Reduction Act and Affordable Care Act Working Together to Lower Health Care Costs
August 17, 2023
In advance of this week’s one-year anniversary of the Inflation Reduction Act (IRA), the Biden-Harris administration released a set of
Administration Provides More Data on First 10 Drugs Subject to Price Negotiation
January 4, 2024
Last month, the office of the Assistant Secretary for Planning and Evaluation (ASPE), a research arm of the Department of
Medicare Rights Joins Legal Fight in Defense of Drug Price Negotiation
November 16, 2023
Last week, the Medicare Rights Center joined with other advocacy organizations to urge a federal court to reject claims by
Medicare Prescription Payment Plan (MPPP) Draft Guidance
October 25, 2023
The Medicare Rights Center (Medicare Rights) appreciates this opportunity to comment on the Medicare Prescription Payment Plan (MPPP) draft guidance. Medicare Rights is a national, nonprofit organization that works to ensure access to affordable and equitable health care for older adults and people with disabilities through counseling and advocacy, educational programs, and public policy initiatives. Each year, Medicare Rights provides services and resources to over three million people with Medicare, family caregivers, and professionals.
Government Watchdog Urges Caution and Monitoring of Part D Rebate Programs
October 19, 2023
Last month, the Government Accountability Office (GAO) recommended that the Centers for Medicare & Medicaid Services monitor the effects of
Part D Drug Negotiations Move Forward
October 12, 2023
Last week, the Centers for Medicare & Medicaid Services (CMS) announced that all of the manufacturers of the first 10
Part D and Medicare Advantage Plans Stable for 2024
September 27, 2023
In advance of the upcoming Medicare Fall Open Enrollment period, beginning October 15, the Biden-Harris administration announced that Medicare Advantage
CMS Announces First 10 Drugs Subject to Price Negotiation
August 31, 2023
On Tuesday, the Centers for Medicare & Medicaid Services (CMS) announced the first 10 Medicare Part D drugs that will
Centers for Medicare & Medicaid Services Announces First 10 Medicare Part D Drugs Subject to Negotiation Under the Inflation Reduction Act (IRA)
August 29, 2023
—Statement by Fred Riccardi, President of the Medicare Rights Center– Washington DC—The Medicare Rights Center applauds a historic milestone achieved
Inflation Reduction Act and Affordable Care Act Working Together to Lower Health Care Costs
August 17, 2023
In advance of this week’s one-year anniversary of the Inflation Reduction Act (IRA), the Biden-Harris administration released a set of